Theron Pharmaceuticals is a biotechnology company based in Sunnyvale, California. They focus on developing long-acting M3 muscarinic antagonist (LAMA) drugs for the treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. Their goal is to create a once-daily inhaled bronchodilator that can be used with different inhalation devices and combined with other drugs. By offering novel combination therapies, Theron Pharmaceuticals aims to improve convenience and clinical outcomes for asthma treatment practices. Founded in 2008, the company's current preclinical development program, TRN-157, targets the treatment of chronic obstructive pulmonary disease and severe asthma.